Ravninski simetričan nehomogen volumno viskozan domenski zid u Lyrinoj geometriji

Some bulk viscous general solutions are found for domain walls in Lyra geometry in the plane symmetric inhomogeneous spacetime. Expressions for the energy density and pressure of domain walls are derived in both cases of uniform and time varying displacement field β. The viscosity coefficient of bulk viscous fluid is assumed to be a power function of mass density. Some physical consequences of the models are also given. Finally, the geodesic equations and acceleration of the test particle are discussed.Našli smo neka opća rješenja za domenske zidove u Lyrinoj geometriji za volumno viskozan nehomogen prostor-vrijeme i ravninsku simetriju. Izveli smo izraze za gustoću energije i tlak domenskih zidova za stalno i za vremenski promjenljivo posmačno polje β. Pretpostavljamo da je koeficijent viskoznosti volumne viskozne tekućine dan s potencijom gustoće mase. Opisujemo neke izvode modela. Na kraju, raspravljamo geodetske jednadžbe i ubrzanje ispitne čestice

Ravninski simetričan nehomogen volumno viskozan domenski zid u Lyrinoj geometriji

Some bulk viscous general solutions are found for domain walls in Lyra geometry in the plane symmetric inhomogeneous spacetime. Expressions for the energy density and pressure of domain walls are derived in both cases of uniform and time varying displacement field β. The viscosity coefficient of bulk viscous fluid is assumed to be a power function of mass density. Some physical consequences of the models are also given. Finally, the geodesic equations and acceleration of the test particle are discussed.Našli smo neka opća rješenja za domenske zidove u Lyrinoj geometriji za volumno viskozan nehomogen prostor-vrijeme i ravninsku simetriju. Izveli smo izraze za gustoću energije i tlak domenskih zidova za stalno i za vremenski promjenljivo posmačno polje β. Pretpostavljamo da je koeficijent viskoznosti volumne viskozne tekućine dan s potencijom gustoće mase. Opisujemo neke izvode modela. Na kraju, raspravljamo geodetske jednadžbe i ubrzanje ispitne čestice

Drug utilization study of patients with dermatophytosis attending dermatology outpatient department in tertiary care teaching hospital in Central India

Background: Dermatophytosis is a common fungal infection in India, with prevalence ranging from 36.6% to 78.4%. Treatment options include topical and systemic antifungal agents such as amphotericin B, clotrimazole, miconazole, luliconazole, itraconazole, and terbinafine. With the availability of newer antifungal drugs, a drug utilization study is necessary to understand prescription patterns and promote rational use. Methods: This is a retrospective observational study conducted among the patients attending outpatient department of dermatology of Indira Gandhi Government Medical College and Mayo Hospital. Prescription of patients with diagnosis of tinea were collected using efficient digital database. These prescriptions were then analysed depending on their demographic profile, treatment and then results were evaluated with the help of MS Excel and results presented as percentage and proportion. Results: Total 3701 patients had tinea with 1658 females and 2043 males with majority of patients from 16 to 30 years of age. 81% medicine were prescribed using brand names with prescription containing maximum antifungal drugs followed by antihistaminic drugs. Most common drug prescribed was terbinafine (29%), followed by luliconazole (27.46%) and itraconazole (17%). Most commonly topical antifungal agents were prescribed as cream (35.80%) followed by as lotion (26.26%). Conclusions: Drug utilisation pattern study like this is very important for studying the varying prescription pattern in treatment of dermatophytosis and to make a first step towards uniform and rational drug prescription

Evaluation of disease distribution and drug utilization for management of psoriasis patients in dermatology OPD of a tertiary care centre: a retrospective observational study

Background: Psoriasis is a chronic skin disorder that can have different clinical presentations. Topical corticosteroids are the primary therapy for psoriasis, but there are many new drug options approved for its treatment. The aim of this study was to assess the prescription patterns and disease distribution of psoriasis patients in a tertiary care center in central India. Methods: We conducted a retrospective observational study of 195 psoriasis patients treated in the Dermatology OPD of a teaching hospital from September 2020 to June 2021. We analyzed patient data for demographics, disease characteristics, and medications prescribed using frequency distributions in Microsoft Excel. Results: Plaque psoriasis was the most common clinical variant among the patients, and the male to female ratio was 1.5:1. February had the highest number of patients treated, indicating an aggravation of symptoms during cold weather. Most patients (93.33%) were prescribed topical corticosteroids, with clobetasol being the most commonly used medication (78%). The average number of drugs per prescription was 5, with other drugs prescribed including emollients (53.33%), vitamin D (31.7%), anti-histamines (21.02%), and methotrexate (5.1%). Conclusions: Topical corticosteroids, particularly clobetasol, were the most commonly prescribed medication for psoriasis patients in this study. Multiple drugs were needed for the management of most patients. The study provides insights into the prescription patterns of psoriasis medications, which may improve patient care and outcomes

Fc gamma receptor polymorphisms in systemic lupus erythematosus and their correlation with the clinical severity of the disease

Receptors for the Fc domains of IgG (Fc \u3b3 R) play a critical role in linking humoral and cellular immune responses. The various Fc \u3b3 R genes may contribute to differences in infectious and immune related diseases in various ethnic populations. Polymorphisms of Fc \u3b3 R mainly Fc \u3b3 R IIA, IIB, IIIA, IIIB have been identified as genetic factors influencing susceptibility to disease or disease course of a prototype autoimmune disease like Systemic Lupus Erythematosus (SLE). Activated and inhibitory Fc \u3b3 Rs seem to play an important role in the pathogenesis of SLE, in initiation of autoimmunity, the subsequent development of inflammatory lesions and finally immune clearance mechanisms. This review focuses on the role of Fc \u3b3 R polymorphism and their association with clinical manifestations and initiation of autoantibody production, inflammatory handling of immune complexes and disease development in SLE patients

APO-1/Fas gene: Structural and functional characteristics in systemic lupus erythematosus and other autoimmune diseases

Systemic lupus erythematosus (SLE) is an autoimmune disorder affecting multiple organ systems. It is characterized by the presence of autoantibodies reactive against various self-antigens. Susceptibility to SLE is found to be associated with many major histocompatibility complex (MHC) and non-MHC genes, one of which is APO-1/Fas gene, which is present on chromosome 10 in humans. The APO-1/Fas promoter contains consensus sequences for binding of several transcription factors that affect the intensity of Fas expression in cells. The mutations in the APO-1/Fas promoter are associated with risk and severity in various autoimmune diseases and other malignancies. The APO-1/Fas receptor is expressed by many cell types. Two forms of APO-1/Fas protein that are involved in regulation of apoptosis have been identified. Fas receptor-mediated apoptosis plays a physiological and pathological role in killing of infected cell targets. In this review, we have focused on APO-1/Fas gene structure, promoter variants and its association with SLE and other autoimmune diseases. Functional aspects of Fas receptor in apoptosis are also discussed